Healthpoint Biotherapeutics today announced that Travis E. Baugh, President and Chief Operating Officer, and Robert Bancroft, Executive Vice President, Strategic and Commercial Development, will present an overview of the Company, its commercial products and its R&D pipeline at the upcoming UBS Global Life Sciences Conference. The presentation is scheduled for the opening day of the conference, Monday, September 19th, at 3 pm (EDT) at the Grand Hyatt in New York City.
|
Tue, 09/13/2011
|
|
Thu, 08/04/2011
Healthpoint Biotherapeutics today announced positive topline results for its Phase IIb clinical trial investigating the efficacy of HP802-247 in venous leg ulcers. Robert Kirsner, MD, PhD, will present the topline results of the study on August 4, 2011, from 1:30-2:00 pm, during the opening day of the inaugural meeting of the American College of Wound Healing and Tissue Repair held at The University of Illinois at Chicago. |
|
Thu, 06/09/2011
Healthpoint Biotherapeutics today announced that it has acquired Regranex® Gel, along with the corresponding intellectual property (including patents), from Systagenix. Terms of the deal were not disclosed. |
|
Wed, 06/08/2011
Healthpoint Biotherapeutics today announced that Travis E. Baugh, President and Chief Operating Officer, and Robert Bancroft, Executive Vice President, Strategic and Commercial Development, will present an overview of the Company, its commercial products and its R&D pipeline at two upcoming investment conferences: Jefferies 2011 Global Healthcare Conference and the 2011 Wells Fargo Securities Healthcare Conference. |
|
Wed, 05/11/2011
Healthpoint Biotherapeutics today announced the introduction of OASIS® Ultra Tri-Layer Matrix, a natural extracellular matrix (ECM) material derived from three layers of porcine small intestinal submucosa (SIS). The three-layer construct of ECM was designed to incorporate increased structure into difficult-to-heal and chronic wounds. |
